Combining Cladribine, Cyclophosphamide, and Prednisone for Low-Grade Lymphoma
Author Information
Author(s): Laurencet F M, Zulian G B, Guetty-Alberto M, Iten P A, Betticher D C, Alberto P
Primary Institution: Division of Oncology, Geneva University Hospitals, Geneva, Switzerland
Hypothesis
The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined.
Conclusion
The study shows that the combination of cladribine, cyclophosphamide, and prednisone is highly active and safe for treating indolent lymphoid malignancies.
Supporting Evidence
- The overall response rate was 88%, with four patients achieving a complete response.
- Twelve patients achieved a partial response.
- Neutropenia WHO grade 4 occurred in two patients.
- WHO grade 3 infection occurred in one patient.
- There were no treatment-related deaths.
Takeaway
Doctors tested a new treatment for some blood cancers and found it worked well and was safe for patients.
Methodology
Nineteen patients received a specific regimen of cladribine, cyclophosphamide, and prednisone over multiple courses.
Limitations
The study had a small sample size and limited follow-up.
Participant Demographics
Patients included nine with chronic lymphocytic leukaemia, seven with non-Hodgkin's lymphoma, and three with macroglobulinaemia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website